Revolution Medicines (RVMD) Enterprise Value (2019 - 2026)

Revolution Medicines' Enterprise Value history runs 8 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.

• On a quarterly basis, Enterprise Value rose 9.25% year-over-year to -$1.9 billion in Q1 2026; TTM through Mar 2026 was -$1.9 billion, a 9.25% increase from a year earlier, with the FY2025 full-year figure at -$2.0 billion, up 11.52% from the prior year.
• Enterprise Value advanced to -$1.9 billion in Q1 2026 per RVMD's latest filing, from -$2.0 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$461.4 million in Q2 2022 and bottomed at -$2.3 billion in Q4 2024.
• The 5-year median for Enterprise Value is -$1.6 billion (2024), against an average of -$1.4 billion.
• Across the five-year window, Enterprise Value advanced 28.61% in 2022 and sank 187.31% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$644.9 million in 2022, then sank by 187.31% to -$1.9 billion in 2023, then dropped by 23.55% to -$2.3 billion in 2024, then grew by 11.52% to -$2.0 billion in 2025, then advanced by 5.81% to -$1.9 billion in 2026.
• Per Business Quant, the three latest RVMD Enterprise Value figures stand at -$1.9 billion (Q1 2026), -$2.0 billion (Q4 2025), and -$1.9 billion (Q3 2025).